Spectrum of Neurologic Complications in COVID-19: An Evidence-Based Review

Soumya Sarkar¹  Puneet Khanna¹  Surya K. Dube²

¹Department of Anaesthesia, Pain Medicine and Critical Care, All India Institute of Medical Sciences, New Delhi, India
²Department of Neuroanaesthesiology, All India Institute of Medical Sciences, New Delhi, India

Address for correspondence  Puneet Khanna, MD, Department of Anaesthesia, Pain Medicine and Critical Care, All India Institute of Medical Sciences, New Delhi 110029, India (e-mail: k.punit@yahoo.com).


Abstract

The world is facing an unprecedented crisis due to the pandemic of current coronavirus disease 2019 (COVID-19). Coronavirus (CoVs) infections not only are always involving the respiratory tract but also possess significant neuroinvasive potential. The literature regarding neuropathogenic potential of human CoVs is sparse. Thus, the number of COVID-19–related neurologic complications is likely to be underestimated. Awareness regarding the possible spectrum of neurologic complications is essential for therapeutic decision-making and individualized treatment and thereby limiting the COVID-19–related morbidity and mortality. The aim of this review is to address the neurologic manifestations of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

Introduction

The world is facing an unprecedented crisis due to the pandemic of current coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Since its origin in late 2019 in China, the infection was disseminated all around the globe by affecting 1,812,734 with a fatality rate of 6.2% (World Health Organization [WHO], April 14, 2020).

The SARS-CoV-2 is an enveloped 29,903 bp single-stranded positive-sense RNA (ss-RNA) coronavirus (CoV). It is a member of the genus Betacoronavirus with an 82% identical genomic sequence with SARS-CoV. The clinical presentation is similar to the previous outbreaks of SARS-CoV in 2002 and MERS-CoV in 2012. However, reproductive number (R0), for SARS-CoV-2, is between 3.6 and 4, indicating higher infectivity. The virus shedding usually peaks at the onset of symptoms and continues even after weeks of recovery. CoV infections not only are always involving the respiratory tract but also possess significant neuroinvasive potential. However, neurologic manifestations of SARS-CoV-2 are not well addressed so far.

Neuroinvasive Potential of SARS-CoV-2

The SARS-CoV-2 infection is mediated by angiotensin-converting enzyme 2 (ACE2) receptor, which is abundantly expressed in airway epithelium, lung parenchyma, and vascular endothelium. The presence of ACE2 receptors over glial cells and neurons makes them a potential target of COVID-19. Lysosomal-related components, cathepsin L, 1-phosphatidylinositol 3-phosphate 5-kinase, also play a crucial role in viral interaction with the host cell. In vitro experiment indicates that the receptor-binding spike protein has been recognized in CD147. Both cathepsin L and CD147 are abundant in the central nervous system (CNS).

SARS-CoV particles have been found in the brain of patients with SARS in 2002 and 2003. Experimental studies on transgenic mice with SARS-CoV and MERS-CoV have demonstrated that the spread of infection in the brain is possible via the olfactory nerve, and thereafter involving the thalamus and brainstem. The CoVs may first invade peripheral nerve terminals, and then affects the CNS via a synapse-connected route.

The transsynaptic transfer has been well established in other CoVs, such as hemagglutinating encephalomyelitis virus 67N strain (HEV67N) and avian bronchitis virus. Viral antigens have been detected in the brainstem, nucleus of the solitary tract, and nucleus ambiguous in mice with intranasal inoculation of avian influenza.

Such neuroanatomic interconnections indicate that the mortality of infected animals may be due to the dysfunction of the cardiorespiratory center. The neuroinvasive propensity of CoVs has been well established. Because of the high genomic similarity, it is quite likely that SARS-CoV-2 also bears a similar potential.
Host–Virus Interaction Routes

Studies on CoVs have demonstrated retrograde neuronal transport as a viable route for viral invasion. A retrograde neuronal transport via vagal from the lungs and enteric nervous system to the CNS has been postulated. However, it is yet to be established for SARS-CoV-2. The hematologic spread is a known route for systemic viral dissemination. Exosomal cellular transport may also be act as another mode of systemic viral dissemination. The SARS-CoV-2 infection leads to decrease CD4+ T cells, thereby promoting granulocyte-macrophage colony-stimulating factor and interleukin-6 (IL-6), which occasionally results in a catastrophic cytokine storm. No experimental data indicate the lymphatic spread of the virus.33

Indirect Neurologic Complications

CoVs generally cause respiratory and enteric diseases. According to the Chinese Centers for Disease Control and Prevention report, 81% of cases presented as mild pneumonia, 14% were characterized by dyspnea and hypoxia, and 5% had respiratory failure, shock, or multiorgan dysfunction. A recent report of Wuhan, China, described that the incidence of confusion and headache was 9 and 8%, respectively, in 99 COVID-19 patients.36

A study from France has reported that the incidence of neurologic complications is ~14% of the patients on admission to the intensive care unit (ICU) and 39% of patients developed the symptoms on discontinuation of sedation and neuromuscular blockade. Another report of 214 patients found 36.4% of patients with various neurologic manifestations. The neurologic symptoms can be categorized into three main areas: CNS symptoms or disease (53 [24.8%]), peripheral nervous system (PNS) symptoms (19 [8.9%]), and muscular symptoms, with elevated serum creatine kinase level above 200 U/L (23 [10.7%]). In patients with CNS symptoms, the most common symptoms were dizziness (36 [16.8%] and headache (28 [13.1%]). In patients with PNS symptoms, the most common symptoms were hypogeusia (12 [5.6%]) and hyposmia (11 [5.1%]). The patients with CNS symptoms had significantly lower lymphocyte, platelet counts, and higher blood urea nitrogen levels than those without CNS symptoms.

Secondary neurologic manifestations of COVID-19 may be the result of pulmonary, renal, hepatic, and cardiovascular injury. The direct and indirect cardiotoxicity due to cytokine storm, hypercoagulability, and myocardial invasion leads to myocardial infarction, heart failure, and arrhythmias, which are primary risk factors for cerebrovascular accident. Mao et al38 reported that 5.7% of severely infected COVID-19 patients died because of acute cerebrovascular disease. Patients with COVID-19 have high D-dimer levels and may be at higher risk of cerebrovascular diseases.

The SARS-CoV-2 infection causes hypoxemia and excessive secretion of inflammatory cytokines, which may lead to ischemic stroke. Helms et al37 have reported two patients with acute ischemic strokes.

Direct Neurologic Complications

Autopsy studies during previous SARS-CoV infections described the presence of viral RNA within the brain tissue of affected individuals. SARS-CoV has also been demonstrated in cerebrospinal fluid (CSF) of severely ill patients. CoV-related meningitis, encephalitis, and acute flaccid paralysis have been reported over the years. The exact mechanism by which SARS-CoV-2 enters the CNS remains unclear. It may disrupt the nasal epithelium and via the olfactory bulb and retrograde transsynaptic spread affects the CNS. A recent experimental study suggests that the direct neuronal injury within brainstem cardiorespiratory centers may be the cause for the acute respiratory failure.42

Primary neuronal infection causes raised secretion of IL-6, an established mediator of the cytokine storm. Thus, neuroinflammation due to systemic dissemination can lead to encephalitis. The systemic inflammation related to metabolic derangements can also cause encephalopathy (Fig. 1).

Acute necrotizing encephalopathy is a rare complication of influenza and related to intracranial cytokine storms, which result in blood–brain barrier disruption. COVID-19–associated acute necrotizing hemorrhagic encephalopathy has been reported.45

Recently the association between COVID-19 and olfactory and gustatory dysfunction has been described. The American Academy of Otolaryngology suggested that anosmia, hyposmia, and dysgeusia be included in the list of COVID-19 screening symptoms for precautionary isolation even in the absence of respiratory disease.

Postinfectious Neurologic Complications

Of the discharged patients, 33% have shown dysexecutive syndrome comprising inattention, disorientation, or poorly organized movements in response to command. It is too early to describe the long-term neurologic complications of exposure to SARS-CoV-2. The persistence of human CoVs in the CNS after the acute phase of the infection may alter host immune responses. Long-term sequelae may lead to increased risk for neuroinflammatory and neurodegenerative diseases. In experimental studies, CoVs have been implicated in the pathogenesis of Parkinson’s disease, acute disseminated encephalomyelitis (ADEM), or multiple sclerosis (MS).

Fig. 1 Pathogenesis of nervous system invasion by coronavirus. ACE2, angiotensin-converting enzyme 2; COVID, coronavirus disease 2019.
In ADEM\textsuperscript{31} and MS\textsuperscript{32} patients, CoV RNA has been detected in the CSF. CoV infections also have been associated with Guillain–Barré syndrome (GBS).\textsuperscript{33} Recently, a case of COVID-19 presenting with acute GBS has been reported.\textsuperscript{34}

The molecular mimicry between CoV and myelin basic protein and direct invasion of leukocytes and other immune cells may aggravate the situation.\textsuperscript{35}

**Neuroimaging and Other Investigations**

Magnetic resonance imaging (MRI) of the brain of the patients with unexplained encephalopathic features has not found any focal signs suggested stroke. However, enhancement in leptomeningeal spaces and bilateral frontotemporal hypoperfusion was noted in the majority of the patients.\textsuperscript{37}

MRI of olfactory bulb has also been found to be inconclusive.\textsuperscript{36}

Nonspecific changes were detected in electroencephalography in a majority of the patients, while a single patient had diffuse bifrontal slowing associated with encephalopathy.\textsuperscript{37}

**Management**

Antiviral drugs (lopinavir/ritonavir, remdesivir), hydroxychloroquine, azithromycin, and other experimental agents, particularly aimed for mitigating the “cytokine storm” seen in severe cases, are currently under evaluation and being used in controlled clinical settings as they have own limitation and drug interactions (\textsuperscript{→}Table 1).\textsuperscript{37} The U.S. Food and Drug Administration (FDA) recently approved the use of COVID-19 convalescent plasma in patients with a severe, life-threatening condition requiring mechanical ventilation, which has shown promising results in small preliminary uncontrolled case series.\textsuperscript{58}

A multicenter, randomized controlled trial of IL-6 receptor blocker: tocilizumab is also under evaluation for severely ill patients with COVID-19.\textsuperscript{59}

The use of immune-modulating therapies in patients with MS, myasthenia gravis, and other neuroimmune disorders has also become a matter of concern.

The National Multiple Sclerosis Society (NMSS)\textsuperscript{30} and the Association of British Neurologists (ABN)\textsuperscript{61} have advised for the judicious use of disease-modifying therapies and immunosuppressive drugs (\textsuperscript{→}Table 2).

It has been advised that patients with preexisting active neurologic disease except for myasthenia gravis or neuromyelitis optica should stop their routine medication during infection with SARS-CoV-2. Even MS patients can safely stop their immunotherapy for up to 4 weeks. However, patients on steroids (<20 mg prednisolone) should continue it and may require higher doses during infection. Hydroxychloroquine and sulfasalazine can be continued safely. Human stem cell transplant and apheresis are strictly avoided.\textsuperscript{61}

**Table 2** Potential risks associated with conventional immunosuppressant therapies\textsuperscript{51}

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravenous immunoglobulin</td>
<td>N</td>
</tr>
<tr>
<td>Beta-interferons</td>
<td>N</td>
</tr>
<tr>
<td>Natalizumab</td>
<td>N</td>
</tr>
<tr>
<td>Glatiramer acetate</td>
<td>N</td>
</tr>
<tr>
<td>Prednisolone: 10–19 mg/d monotherapy</td>
<td>L</td>
</tr>
<tr>
<td>&gt;20 mg/d</td>
<td>H</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>M</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>H</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td>M/H</td>
</tr>
<tr>
<td>Cyclophosphamide IV or oral</td>
<td>H</td>
</tr>
</tbody>
</table>

Abbreviations: H, high risk; IV, intravenous; L, low risk; M, moderate risk; N, no increased risk.

The full clinical spectrum of COVID-19 remains to be described. There is a higher propensity for SARS-CoV-2 to have a similar potential for extrapulmonary and CNS invasion. It is very difficult to identify whether these neurologic features are due to critical illness-related encephalopathy, cytokines, or the effect or withdrawal of medication, and specific to SARS-CoV-2 infection. Because of the paucity of current medical literature regarding the neuropathogenic potential of human CoVs, the number of COVID-19–related neurologic complications is likely underestimated.

Awareness regarding the possible spectrum of neurologic complications can guide therapeutic decision-making and individualized treatment and thereby limiting the COVID-19–related morbidity and mortality.
**Conflict of Interest**

None declared.

**References**

41 Desforges M, Le Coupanc A, Dubpeau P, et al. Human corona-
viruses and other respiratory viruses: underestimated oppor-
42 Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain
MJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect
regarding pathogenesis, immune responses, and out-
43 Eerta M, Quintana A, Hidalgo J. Interleukin-6, a major cytoke
44 Siami S, Annane D, Sharshar T. The encephalopathy in sepsi.
COVID-19-associated acute hemorrhagic necrotizing enceph-
radiol.2020201187
and taste disorders in SARS-CoV-2 patients: a cross-sectional
47 Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to
coronavirus in patients with Parkinson’s disease. Mov Disord
48 Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. Detection
of coronavirus in the central nervous system of a child
with acute disseminated encephalomyelitis. Pediatrics 2004;
113(1 Pt 1):e73–e76
49 Murray RS, Brown B, Brian D, Cabirac GF. Detection of corona-
virus RNA and antigen in multiple sclerosis brain. Ann Neurol
1992;31(5):525–533
50 Stewart JN, Mounir S, Talbot PJ. Human coronavirus gene
expression in the brains of multiple sclerosis patients. Virology
51 Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. Detection
of coronavirus in the central nervous system of a child with
acute disseminated encephalomyelitis. Pediatrics 2004;
113(1 Pt 1):e73–e76
52 Cristallo A, Gambaro F, Biamonti G, Ferrante P, Battaglia
M, Cereda PM. Human coronavirus polyadenylated RNA
sequences in cerebrospinal fluid from multiple sclerosis
53 Algahtani H, Subahi A, Shirah B. Neurological complications
of Middle East respiratory syndrome coronavirus: a report of
two cases and review of the literature. Case Rep Neurol Med
2016;2016:3502683
54 Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome
associated with SARS-CoV-2 infection: causality or coinci-
55 Chew FT, Ong SY, Hew CL. Severe acute respiratory syndrome
coronavirus and viral mimicry. Lancet 2003;361(9374):2081
56 Galoughah MK, Ghorbani J, Bakhshayeshkaram M, Naeini AS,
Haseli S. Olfactory bulb magnetic resonance imaging in SARS-
57 Liverpool COVID-19 Interactions [Internet]. Covid19-
druginteractions.org. 2020 [cited 15 May 2020]. Available at:
http://www.covid19-druginteractions.org/. Accessed May 20,
2020
patients with COVID-19 with convalescent plasma. JAMA
2020;323(16):1582-1589
59 Chinese Clinical Trial Registry. A multicenter, randomized
controlled trial for the efficacy and safety of tocilizumab in
the treatment of new coronavirus pneumonia (COVID-19).
Available at: http://www.chictr.org.cn/showprojen.aspx?proj=
49409. Accessed May 20, 2020
60 National Multiple Sclerosis Society. Disease Modifying
Treatment Guidelines for Coronavirus (COVID-19). National
Multiple Sclerosis Society. Available at: https://www.
nationalmssociety.org/What-you-need-to-know-about-
Coronavirus-(COVID-19)/DMT-Guidelines-for-Coronavirus-
61 Association of British Neurologists. Association of British
Neurologists Guidance on COVID-19 for people with neuro-
logical conditions, their doctors and carers. 2020. Available at:
67508AE6-4CBC-4DDB-A684-116ED03BFED34/ABN_